National Bank of Canada
ARCT icon

National Bank of Canada’s Arcturus Therapeutics ARCT Stock Holding History

National Bank of Canada’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,532
Closed -$93.9K – 2842
2024
Q4 		$93.9K Buy
5,532
+4,784
+640% +$90.1K ﹤0.01% 1771
2024
Q3 		$17.4K Sell
748
-52
-7% -$1.11K ﹤0.01% 1974
2024
Q2 		$18.9K Buy
+800
New +$24.3K ﹤0.01% 1982
2023
Q4 		– Sell
-70
Closed -$1.8K – 2721
2023
Q3 		$1.8K Hold
70
– – ﹤0.01% 2520
2023
Q2 		$2.01K Hold
70
– – ﹤0.01% 2468
2023
Q1 		$1.68K Hold
70
– – ﹤0.01% 2469
2022
Q4 		$1.19K Hold
70
– – ﹤0.01% 2568
2022
Q3 		$1K Hold
70
– – ﹤0.01% 2570
2022
Q2 		$1K Hold
70
– – ﹤0.01% 2669
2022
Q1 		$2K Sell
70
-50
-42% -$1.28K ﹤0.01% 2689
2021
Q4 		$4K Buy
+120
New +$4.89K ﹤0.01% 2563

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

National Bank of Canada's ARCT Position: Q1 2025 in Review

National Bank of Canada sold out of Arcturus Therapeutics (ARCT) in Q1 2025, closing a stake of 5,532 shares — an estimated $93.9K sold.

National Bank of Canada first reported a position in ARCT in Q4 2021 and held it in 11 quarters. The position peaked at $93.9K in Q4 2024. 144 funds tracked by Wall St. Rank hold ARCT as of Q1 2025.

  • National Bank of Canada reported no remaining Arcturus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • National Bank of Canada sold 5,532 Arcturus Therapeutics shares in Q1 2025, an estimated $93.9K.
  • National Bank of Canada first reported a position in Arcturus Therapeutics in Q4 2021 and held it in 11 quarters.
  • National Bank of Canada's Arcturus Therapeutics position peaked at $93.9K in Q4 2024.
  • 144 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2025.

Based on National Bank of Canada's 13F filing for Q1 2025, filed 12 May 2025.